Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study.
Nappo F, Fornaro L, Pompella L, Catanese S, Lavacchi D, Spallanzani A, Cappetta A, Puzzoni M, Murgioni S, Barsotti G, Tirino G, Pellino A, Vivaldi C, Strippoli A, Aprile G, Di Donato S, Mazza E, Prisciandaro M, Antonuzzo L, Zagonel V, Cascinu S, De Vita F, Lonardi S. Nappo F, et al. Among authors: cascinu s. J Cancer Res Clin Oncol. 2023 Aug;149(9):6601-6611. doi: 10.1007/s00432-023-04636-y. Epub 2023 Feb 16. J Cancer Res Clin Oncol. 2023. PMID: 36795195 Free PMC article.
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferraù F, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G. Morabito A, et al. Among authors: cascinu s. Breast Cancer Res Treat. 2003 Mar;78(1):29-36. doi: 10.1023/a:1022197109592. Breast Cancer Res Treat. 2003. PMID: 12611454 Clinical Trial.
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Loupakis F, Masi G, Fornaro L, Vasile E, Allegrini G, Fontana E, Granetto C, Salvatore L, Mentuccia L, Andreuccetti M, Cortesi E, Merlano M, Cascinu S, Falcone A. Loupakis F, et al. Among authors: cascinu s. Cancer Chemother Pharmacol. 2010 Aug;66(3):559-66. doi: 10.1007/s00280-009-1196-1. Epub 2010 Mar 17. Cancer Chemother Pharmacol. 2010. PMID: 20237927 Clinical Trial.
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators. Taieb J, et al. Lancet Oncol. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11. Lancet Oncol. 2014. PMID: 24928083 Free article. Clinical Trial.
657 results